Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Wednesday, October 30th,Zacks Dividends reports. Shareholders of record on Friday, December 13th will be given a dividend of 0.77 per share by the biopharmaceutical company on Monday, December 30th. This represents a $3.08 annualized dividend and a yield of 3.34%. The ex-dividend date is Friday, December 13th.

Gilead Sciences has increased its dividend payment by an average of 3.3% annually over the last three years. Gilead Sciences has a dividend payout ratio of 41.1% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $7.38 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 41.7%.

Gilead Sciences Price Performance

GILD opened at $92.34 on Wednesday. The firm has a market cap of $115.08 billion, a PE ratio of 1,026.00, a P/E/G ratio of 2.86 and a beta of 0.18. The stock has a 50-day moving average price of $89.33 and a 200-day moving average price of $78.89. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences will post 4.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Wolfe Research assumed coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Citigroup started coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 476,591 shares of company stock valued at $43,747,615. 0.29% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.